HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IKT
Inhibikase Therapeutics, Inc.
There isn't enough reported data to score IKT yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IKT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
IKT's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IKT PE Valuation
IKT has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IKT Forward outlook
There aren't enough analyst estimates for IKT to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
IKT has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus IKT down 115%.
IKT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$2.68 | +$1.33 |
| Q2 2024 | -$2.89 | +$1.34 |
| Q1 2024 | -$3.34 | +$0.86 |
| Q4 2023 | -$3.57 | +$0.75 |
| Q3 2023 | -$4.01 | +$0.13 |
| Q2 2023 | -$4.23 | -$0.09 |
| Q1 2023 | -$4.20 | +$0.18 |
| Q4 2022 | -$4.32 | +$0.54 |
IKT is still losing money, but far less than before: $0.41 per share over the past year, against $4.86 at its worst in late 2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
IKT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $1 | -100% |
| Q3 2023 | $79.6K | +991% |
| Q2 2023 | $116.4K | +1677% |
| Q1 2023 | $64.5K | +40% |
| Q4 2022 | $63.6K | +3170% |
| Q3 2022 | $7.3K | -98% |
| Q2 2022 | $6.6K | -100% |
| Q1 2022 | $46K | -97% |
IKT's revenue is shrinking: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2023 | -440356600% | -440349780 points |
| Q3 2023 | -5993% | +55906 points |
| Q2 2023 | -5328% | +65489 points |
| Q1 2023 | -7308% | +2774 points |
| Q4 2022 | -6820% | +252515 points |
| Q3 2022 | -61900% | -60538 points |
| Q2 2022 | -70817% | -70624 points |
| Q1 2022 | -10081% | -9895 points |
IKT's operating margin was −440356600% last quarter, down 440349780 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IKT on cash generation, producing positive trailing cash flow while its opponent burns cash.
IKT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.4M | -$6.8M |
| Q2 2026 | -$12.4M | -$6.9M |
| Q1 2026 | -$12.1M | -$7.9M |
| Q4 2025 | -$7.5M | -$2.2M |
| Q3 2025 | -$10.6M | -$5.7M |
| Q1 2025 | -$4.1M | -$249.9K |
| Q4 2024 | -$5.3M | -$1.9M |
| Q3 2024 | -$4.9M | -$776K |
IKT has burned cash in almost every quarter: −$49M over the past year, against −$26M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IKT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IKT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +22.4M shares |
| 1 year | +119% | +107M shares |
| 3 years | +4195% | +192M shares |
| 5 years | +14158% | +196M shares |
| Available history | +14344% | +196M shares |
IKT has 197M diluted shares, up 119% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IKT Net Leverage
IKT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IKT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.4 | Neutral |
| Stochastic | 6.5 | Oversold |
IKT's weekly RSI is 35 (neutral) and its Stochastic is 6 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IKT PE vs Healthcare Sector
IKT has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IKT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.73 | 12% below |
| 20 week MA | $2.07 | 26% below |
| 50 week MA | $1.89 | 19% below |
| 100 week MA | $1.95 | 22% below |
| 200 week MA | $2.13 | 28% below |
IKT is in a downtrend: it's below all five of its weekly moving averages, and 28% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IKT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.8 | $58.8 | 0% |
| 2021 | $58.8 | $9.42 | -84% |
| 2022 | $9.42 | $2.97 | -68% |
| 2023 | $2.97 | $1.27 | -57% |
| 2024 | $1.27 | $3.05 | +140% |
| 2025 | $3.05 | $2.00 | -34% |
| 2026 YTD | $2.00 | $1.53 | -24% |
IKT has the edge over HIMS on returns for 2026, with the stronger performance.